Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 11/20 | 0.82 |
| ▸ | IGF1R | P08069 | 8/20 | 0.59 |
| ▸ | JAK2 | O60674 | 1/20 | 0.55 |
| ▸ | PAK3 | O75914 | 2/20 | 0.53 |
| ▸ | PAK1 | Q13153 | 2/20 | 0.53 |
| ▸ | PAK2 | Q13177 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3039039 | 0.90 | NTRK1 (1.00) | NTRK1IGF1RJAK2 | |
| SCHEMBL3028856 | 0.90 | NTRK1 (1.00) | NTRK1IGF1RJAK2 | |
| SCHEMBL3033789 | 0.90 | NTRK1 (0.80) | NTRK1IGF1RJAK2PAK3PAK1 | |
| SCHEMBL3029858 | 0.85 | NTRK1 (0.79) | NTRK1IGF1RJAK2PAK3PAK1 | |
| SCHEMBL3040607 | 0.85 | NTRK1 (0.79) | NTRK1IGF1RJAK2PAK3PAK1 | |
| SCHEMBL3028618 | 0.85 | NTRK1 (0.79) | NTRK1IGF1RJAK2PAK3PAK1 | |
| SCHEMBL4072338 | 0.84 | NTRK1 (0.79) | NTRK1IGF1R | |
| SCHEMBL3338062 | 0.84 | NTRK1 (0.79) | NTRK1IGF1R | |
| SCHEMBL4064474 | 0.84 | NTRK1 (0.79) | NTRK1IGF1R | |
| SCHEMBL29794741 | 0.84 | NTRK1 (0.79) | NTRK1IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287437-A1 | Pyrazolylaminopyrimidine Derivatives Useful as Tyrosine Kinase Inhibitors | ASTRAZENECA AB (SE) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287437-A1 | Pyrazolylaminopyrimidine Derivatives Useful as Tyrosine Kinase Inhibitors | ABL1, FLT3, ERBB2 | NTRK1 574/4885IGF1R 407/4885JAK2 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.